References

1. United States Bureau of the Census. Current Population Reports, Series P23-194, Population Profile of the United States: 1997. US Government Printing Office, Washington, DC, 1998.
2. Evans WJ, Evans MI, Hajj SN. The aging population. In: Hajj SN, Evans WJ, eds. Clinical Postreproductive Gynecology. East Norwalk, Conn: Appleton and Lange, 1993:3.
3. Burnett RG. Menopause: All Your Questions Answered. Chicago, Ill: Contemporary Books, Inc; 1987:3.
4. Soules MR, Bremmer WJ. The menopause and climacteric: endocrinologic basis and associated symptomatology. J Am Geriatr Soc. 1982;30:547-561.
5. 1997 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 1997.
6. Hammond CB. Therapeutic Options for Menopausal Health. Durham, NC: Duke University Department of Continuing Education; 1998.
7. Scura KW, Whipple B. How to provide better care for the postmenopausal woman. Am J Nurs. 1997;97(4):36-43.
8. Oldenhave A, Jaszmann LJB, Haspels AA, et al. Impact of climacteric on well-being: A survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol. 1993;168:772-780.
9. Judd HL, Meldrum DR. Physiology and pathophysiology of menstruation and menopause. In: Romney SL, Gray MJ, Little AB, et al, eds. Gynecology and Obstetrics: The Health Care of Women. 2nd ed. New York, NY: McGraw-Hill; 1981:885-907.
10. Bachman GA. Vasomotor flushes in menopausal women. Am J Obstet Gynecol. 1999;180(3):S312-S316.
11. Brincat M, Moniz CF, Studd JWW, et al. The long-term effects of the menopause and the administration of sex hormones on skin collagen and skin thickness. Br J Obstet Gynaecol. 1985;92:255-259.
12. Maheux R, Naud F, Rioux M, et al. A randomized double-blind, placebo-controlled study on the effect of conjugated estrogens on skin thickness. Am J Obstet Gynecol. 1994;170:642-649.
13. Baird DT, Fraser IS. Blood production and ovarian secretion rates of estradiol-17 beta and estrone in women throughout the menstrual cycle. J Clin Endocrinol Metab. 1974;38:1009-1017.
14. Lloyd CW, Lobotsky J, Baird DT, et al. Concentration of conjugated estrogens, androgens, and gestagens in ovarian and peripheral venous plasma in women: the normal menstrual cycle. J Clin Endocrinol Metab. 1971;32:155-166.
15. Rousseau ME. Women's midlife health: reframing menopause. J Nurse Midwifery. 1998;43(3):208-223.
16. Sherman BM, West JH, Korenman SG. The menopausal transition: analysis of LH, FSH, estradiol, and progesterone concentrations during menstrual cycles of older women. J Clin Endocrinol Metab. 1976;42:629-636.
17. Upton GV. The perimenopause: physiologic correlates and clinical management. J Reprod Med. 1982;27:1-27.
18. Kletzky OA, Nakamura RM, Thorneycroft IH, Mishell DR Jr. Log normal distribution of gonadotropins and ovarian steroid values in the normal menstrual cycle. Am J Obstet Gynecol. 1975;121:688-694.
19. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. Engl J Med. 1995;332:1589-1593.
20. Birge SJ, Mortel KF. Estrogen and the treatment of Alzheimer's Disease. Am J Med. 1997;103(3A):36S-45S.
21. Paganini-Hill A. The risks and benefits of estrogen replacement therapy: Leisure World. Int J Fertil Menopausal Stud. 1995;40(suppl 1):54-62.
22. Grodstein F, Colditz GA, Stampfer MJ. Post-menopausal hormone use and tooth loss: a prospective study. J Am Dent Assoc. 1996;127:370-377.
23. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. Engl J Med. 1996;335:453-461.
24. Notelovitz M. Urogenital aging: solutions in clinical practice. Int J Gynaecol Obstet. 1997;59(suppl 1):S35-S39.
25. McDonnell DP, Norris JD. Analysis of the molecular pharmacology of estrogen receptor agonists and antagonists provides insights into the mechanism of action of estrogen and bone. Osteoporosis Int. 1997(suppl 1):S29-S34.
26. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol. 1995;9:659-669.
27. Katzenellenbogen JA, O'Malley BW, Katzenellenbogen BS. Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol Endocrinol. 1996;10:119-131.
28. Love RR, Wiebe DA, Newcombe PA, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med. 1991;115:860-864.
29. Love RR, Mazess RR, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. Engl J Med. 1992;326:852-856.
30. Draper MW, Flowers DE, Huster WJ, Neild JA. Effects of raloxifene (LY139481 HCl) on biochemical markers of bone and lipid metabolism in healthy post-menopausal women. Aalborg: Handelstrykkeriet, 1993.
31. Yang NN, Bryant HU, Hardikar S, et al. Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: potential mechanism for estrogen- or raloxifene-mediated bone maintenance. Endocrinology. 1996;137:2075-2084.
32. Shughrue PJ, Komm B, Merchenthaler I. The distribution of estrogen receptor-beta mRNA in the rat hypothalamus. Steroids. 1996;61:678-681.
33. Shughrue PJ, Lane MV, Merchenthaler I. Comparative distribution of estrogen receptor-alpha and -beta mRNA in the rat central nervous system. J Comp Neurol. 1997;388:507-525.
34. Allan GF, Leng X, Tsai SY, et al. Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. J Biol Chem. 1992:267:19513-19520.
35. Beekman JM, Allan GF, Tsai SY, Tsai MJ, O'Malley BW. Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. Mol Endocrinol. 1993;7:1266-1274.
36. Lock M. Menopause: lessons from anthropology. Psychosom Med. 1998;60:410-419.
37. Hautman MA. Changing womanhood: perimenopause among Filipina-Americans. J Obstet Gynecol Neonatal Nurs. 1996;25:667-673.
38. Im EO, Lipson JG. Menopausal transition of Korean immigrant women: a literature review. Health Care Women Int. 1997;18:507-520.
39. Bartman BA, Moy E. Racial differences in estrogen use among middle-aged and older women. Women's Health Issues. 1998 (Jan/Feb);32-44.
40. Jahnige K, Fiebach . Postmenopausal estrogen use among African American and white patients at an urban clinic. J Women's Health. 1997;6:93-101.
41. Rousseau ME, McCool WF. The menopausal experience of African American women: overview and suggestions for research. Health Care Women Int. 1997;18:233-250.
42. Barile LA. Theories of menopause. Brief comparative synopsis. J Psychosoc Nurs Ment Health Serv. 1997;35(2):36-39.
43. Faulkner DL, Young C, Hutchins D, McCollam JS. Patient noncompliance with hormone replacement therapy: a nationwide estimate using a large prescription claims database. Menopause. 1998;5:226-229.
44. Kronenberg F. Hot flashes. In: Lobo RE, ed. Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. New York, NY: Raven Press; 1994:97-117.
45. Silva NL, Boulant JA. Effects of testosterone, estradiol and temperature on neurons in preoptic tissue slices.
46. Am J Physiol. 1986;250:R625-R632. Israel SL, Schneller O. The thermogenic property of progesterone. Fertil Steril. 1950;1:53-64.
47. Altura BM. Sex as a factor influencing the responsiveness of arterioles to catecholamines. Eur J Pharmacol. 1972;20:261-265.
48. Erlik Y, Tataryn IV, Meldrum DR, et al. Association of waking episodes with menopausal hot flushes. JAMA. 1981;245:1741-1744.
49. Millonig VL. Menopause: health promotion opportunities for the occupational health nurse. AAOHN Journal. 1996;44:585-597.
50. Fantl JA, Cardozo L, McClish DK. Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. First report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol. 1994;83:12-18.
51. Rosen RC, Taylor JF, Leiblum SR, Bachman GA. Prevalence of sexual dysfunction in women: results of a survey study of 329 women in an outpatient gynecological clinic. J Sex Marital Ther. 1993;19:171.
52. Dennerstein L, Burrows GD. Hormone replacement therapy and sexuality in women. Clin Endocrinol Metab. 1982;11:661-679.
53. Pariser SF, Niedermier JA. Sex and the mature woman. J Women's Health. 1998;7:849-859.
54. Yankelovich Partners, Inc. Vitality for life survey. 1999.
55. Cook M. Nursing assessment for the older woman. RN. 1994;September:40-44.
56. Sherwin BB, Gelfand MM. Sex steroids and affect in the surgical menopause: a double-blind, cross-over study. Psychoneuroendocrinology. 1985;10:325-335.
57. Sherwin BB. Hormones, mood, and cognitive function in postmenopausal women. Obstet Gynecol. 1996;87(suppl 2):20S-26S.
58. Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol. 1994;83:686-692.
59. Clinical Practice Guidelines: Postmenopausal Hormone Therapy. Position paper. Philadelphia, Penn: American College of Physicians; 1995.